Login to Your Account

InterMune Divesting Infergen For $135.5M, Cuts Work Force

By Randall Osborne

Wednesday, November 30, 2005
Six months after selling its anti-infective drug Amphotec to Three Rivers Pharmaceuticals LLC, InterMune Inc. has agreed to dispense U.S. and Canadian rights to its hepatitis C compound Infergen to Valeant Pharmaceuticals International Inc. for about $135.5 million in cash. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription